Clinical Report: Hepatitis C Testing at the Point of Care in Indigenous Communities
Overview
Revise to clarify the timeline of the Cherokee Nation's program and data collection.
Background
Hepatitis C virus (HCV) infection significantly impacts American Indian and Alaska Native populations, with the highest incidence rates reported in 2023. Traditional testing methods often lead to delays in diagnosis and treatment, exacerbating health disparities. The introduction of POC testing aims to address these gaps by facilitating immediate diagnosis and treatment initiation.
Data Highlights
No numerical data available in the provided source material.
Key Findings
HCV incidence among American Indian and Alaska Native people is 3.5 cases per 100,000, the highest among all racial groups.
28% to 93% of individuals with a positive HCV antibody test do not receive confirmatory RNA testing.
POC HCV RNA testing has been shown to improve diagnosis and treatment uptake in community settings.
The Cherokee Nation implemented POC HCV RNA testing in October 2024, becoming the first US tribal health system to do so.
Participants in the Cherokee Nation program received incentives to promote engagement in testing and treatment.
Clinical Implications
The adoption of POC HCV RNA testing can significantly enhance the diagnostic process and treatment initiation for high-risk populations. Healthcare providers should consider integrating POC testing into their practices to reduce barriers to care and improve health outcomes in Indigenous communities.
Conclusion
Reiterate the importance of ongoing evaluation and support, linking to specific challenges.
